Both Intec Pharma Ltd. (NASDAQ:NTEC) and Intra-Cellular Therapies Inc. (NASDAQ:ITCI) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Demonstrates Intec Pharma Ltd. and Intra-Cellular Therapies Inc. earnings per share (EPS), gross revenue and valuation.
Table 2 hightlights the return on equity, net margins and return on assets of the two companies.
The Recommendations and Ratings for Intec Pharma Ltd. and Intra-Cellular Therapies Inc. are featured in the next table.
Competitively Intra-Cellular Therapies Inc. has an average price target of $27, with potential upside of 124.25%.
Institutional and Insider Ownership
Intec Pharma Ltd. and Intra-Cellular Therapies Inc. has shares owned by institutional investors as follows: 39.64% and 78.6%. Insiders owned 11.81% of Intec Pharma Ltd. shares. Competitively, Intra-Cellular Therapies Inc. has 3.8% of it’s share owned by